Trial reportThe journal of allergy and clinical immunology. In practice
Dietary Fatty Acid Modification for the Treatment of Aspirin-Exacerbated Respiratory Disease: A Prospective Pilot Trial.
Trial report in The journal of allergy and clinical immunology. In practice. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 42 citations in OpenAlex.
- Article
- Adult-onset asthma, allergy, and aspirin hypersensitivity associate with self-reported food avoidance.European clinical respiratory journal · 2024Article
- Nonsteroidal antiinflammatory drug-exacerbated respiratory disease: molecular mechanism, management and treatment.Frontiers in allergy · 2024Review
- Association between circulating fatty acid metabolites and asthma risk: a two-sample bidirectional Mendelian randomization study.BMC medical genomics · 2023Article
- Lung Function and Asthma Clinical Control in N-ERD Patients, Three-Year Follow-Up in the Context of Real-World Evidence.Journal of asthma and allergy · 2023Article
- The role of oxylipins in NSAID-exacerbated respiratory disease (N-ERD).Advances in pharmacology (San Diego, Calif.) · 2023Article
- Review
- Innate immune cell dysregulation drives inflammation and disease in aspirin-exacerbated respiratory disease.The Journal of allergy and clinical immunology · 2021Review
- Lipid-mediated innate lymphoid cell recruitment and activation in aspirin-exacerbated respiratory disease.Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology · 2021Review
- Therapeutic Options for Chronic Rhinosinusitis in N-ERD Patients.Frontiers in allergy · 2021Review
- Pathomechanisms of AERD-Recent Advances.Frontiers in allergy · 2021Review
- Aspirin Actions in Treatment of NSAID-Exacerbated Respiratory Disease.Frontiers in immunology · 2021Review
- Aspirin-exacerbated respiratory disease: A review.Laryngoscope investigative otolaryngology · 2020Review
- NSAID-ERD Syndrome: the New Hope from Prevention, Early Diagnosis, and New Therapeutic Targets.Current allergy and asthma reports · 2020Review
- Effect of Zileuton Treatment on Sinonasal Quality of Life in Patients with Aspirin-Exacerbated Respiratory Disease.American journal of rhinology & allergy · 2019Article
- Clinical updates in aspirin-exacerbated respiratory disease.Allergy and asthma proceedings · 2019Review
- Inflammation resolution and specialized pro-resolving lipid mediators in chronic rhinosinusitis.Expert review of clinical immunologyReview
- Can Diet Modification Be an Effective Treatment in Aspirin-Exacerbated Respiratory Disease?The journal of allergy and clinical immunology. In practiceArticle
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundThe high levels of eicosanoid production and the clinical efficacy of leukotriene-modifying pharmacotherapies for patients with aspirin-exacerbated respiratory disease (AERD) suggest that other interventions targeting arachidonic acid dysregulation may also improve disease control.
objectiveTo assess the utility of a high omega-3/low omega-6 diet for the treatment of AERD.
methodsProspective, nonblinded dietary intervention in 10 adult patients with AERD at Brigham and Women's Hospital in Boston, MA. The primary objective was for subjects to reduce dietary omega-6 fatty acid consumption to less than 4 g/d and increase omega-3 intake to more than 3 g/d. The primary outcome was change in urinary leukotriene E
resultsOf the 10 subjects who screened for the study, all 10 completed the dietary intervention. Urinary leukotriene E
conclusionsA high omega-3/low omega-6 diet may be an appropriate adjunct treatment option for patients with AERD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.